TY - JOUR AU - Cella, D. AU - Li, J. Z. AU - Cappelleri, J. C. AU - Bushmakin, A. AU - Charbonneau, C. AU - Kim, S. T. AU - Chen, I. AU - Motzer, R. J. PY - 2008 DA - 2008// TI - Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.5145 DO - 10.1200/JCO.2007.13.5145 ID - Cella2008 ER - TY - JOUR AU - Su, D. AU - Stamatakis, L. AU - Singer, E. A. AU - Srinivasan, R. PY - 2014 DA - 2014// TI - Renal cell carcinoma: molecular biology and targeted therapy JO - Curr Opin Oncol VL - 26 UR - https://doi.org/10.1097/CCO.0000000000000069 DO - 10.1097/CCO.0000000000000069 ID - Su2014 ER - TY - JOUR AU - Molina, A. M. AU - Hutson, T. E. AU - Larkin, J. AU - Gold, A. M. AU - Wood, K. AU - Carter, D. AU - Motzer, R. AU - Michaelson, M. D. PY - 2014 DA - 2014// TI - A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC) JO - Cancer Chemother Pharmacol VL - 73 UR - https://doi.org/10.1007/s00280-013-2339-y DO - 10.1007/s00280-013-2339-y ID - Molina2014 ER - TY - JOUR AU - Escudier, B. AU - Porta, C. AU - Schmidinger, M. AU - Algaba, F. AU - Patard, J. J. AU - Khoo, V. AU - Eisen, T. AU - Horwich, A. PY - 2014 DA - 2014// TI - Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu259 DO - 10.1093/annonc/mdu259 ID - Escudier2014 ER - TY - JOUR AU - Iacovelli, R. AU - Carteni, G. AU - Sternberg, C. N. AU - Milella, M. AU - Santoni, M. AU - Lorenzo, G. AU - Ortega, C. AU - Sabbatini, R. AU - Ricotta, R. AU - Messina, C. PY - 2013 DA - 2013// TI - Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2013.02.032 DO - 10.1016/j.ejca.2013.02.032 ID - Iacovelli2013 ER - TY - CHAP AU - Jurgens, H. AU - Tiigi, R. AU - Ojamaa, K. AU - Pokker, H. AU - Innos, K. AU - Padrik, P. PY - 2014 DA - 2014// TI - A population-based analysis of changes in therapy of metastatic renal cell carcinoma (mRCC) BT - Journal of clinical oncology ID - Jurgens2014 ER - TY - JOUR AU - Soerensen, A. V. AU - Donskov, F. AU - Hermann, G. G. AU - Jensen, N. V. AU - Petersen, A. AU - Spliid, H. AU - Sandin, R. AU - Fode, K. AU - Geertsen, P. F. PY - 2014 DA - 2014// TI - Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2 JO - Eur J Cancer VL - 50 UR - https://doi.org/10.1016/j.ejca.2013.10.010 DO - 10.1016/j.ejca.2013.10.010 ID - Soerensen2014 ER - TY - JOUR AU - Eichelberg, C. AU - Vervenne, W. L. AU - Santis, M. AU - Fischer Von Weikersthal, L. AU - Goebell, P. J. AU - Lerchenmuller, C. AU - Zimmermann, U. AU - Bos, M. M. AU - Freier, W. AU - Schirrmacher-Memmel, S. PY - 2015 DA - 2015// TI - SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer JO - Eur Urol VL - 68 UR - https://doi.org/10.1016/j.eururo.2015.04.017 DO - 10.1016/j.eururo.2015.04.017 ID - Eichelberg2015 ER - TY - JOUR AU - Felici, A. AU - Bria, E. AU - Tortora, G. AU - Cognetti, F. AU - Milella, M. PY - 2012 DA - 2012// TI - Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR JO - Expert Rev Anticancer Ther VL - 12 UR - https://doi.org/10.1586/era.12.149 DO - 10.1586/era.12.149 ID - Felici2012 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. AU - Group, P. PY - 2009 DA - 2009// TI - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement JO - BMJ VL - 339 UR - https://doi.org/10.1136/bmj.b2535 DO - 10.1136/bmj.b2535 ID - Moher2009 ER - TY - JOUR AU - Hozo, S. P. AU - Djulbegovic, B. AU - Hozo, I. PY - 2005 DA - 2005// TI - Estimating the mean and variance from the median, range, and the size of a sample JO - BMC Med Res Methodol VL - 5 UR - https://doi.org/10.1186/1471-2288-5-13 DO - 10.1186/1471-2288-5-13 ID - Hozo2005 ER - TY - JOUR AU - Krajewski, K. M. AU - Nishino, M. AU - Ramaiya, N. H. AU - Choueiri, T. K. PY - 2015 DA - 2015// TI - RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy JO - AJR Am J Roentgenol VL - 204 UR - https://doi.org/10.2214/AJR.14.13236 DO - 10.2214/AJR.14.13236 ID - Krajewski2015 ER - TY - JOUR AU - Higgins, J. P. AU - Thompson, S. G. AU - Deeks, J. J. AU - Altman, D. G. PY - 2003 DA - 2003// TI - Measuring inconsistency in meta-analyses JO - BMJ VL - 327 UR - https://doi.org/10.1136/bmj.327.7414.557 DO - 10.1136/bmj.327.7414.557 ID - Higgins2003 ER - TY - JOUR AU - Al-Marrawi, M. Y. AU - Rini, B. I. AU - Harshman, L. C. AU - Bjarnason, G. AU - Wood, L. AU - Vaishampayan, U. AU - MacKenzie, M. AU - Knox, J. J. AU - Agarwal, N. AU - Al-Harbi, H. PY - 2013 DA - 2013// TI - The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients JO - Targ Oncol VL - 8 UR - https://doi.org/10.1007/s11523-012-0252-7 DO - 10.1007/s11523-012-0252-7 ID - Al-Marrawi2013 ER - TY - JOUR AU - Hainsworth, J. D. AU - Rubin, M. S. AU - Arrowsmith, E. R. AU - Khatcheressian, J. AU - Crane, E. J. AU - Franco, L. A. PY - 2013 DA - 2013// TI - Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial JO - Clin Genitourin Cancer VL - 11 UR - https://doi.org/10.1016/j.clgc.2013.04.006 DO - 10.1016/j.clgc.2013.04.006 ID - Hainsworth2013 ER - TY - JOUR AU - Matrana, M. R. AU - Duran, C. AU - Shetty, A. AU - Xiao, L. AU - Atkinson, B. J. AU - Corn, P. AU - Pagliaro, L. C. AU - Millikan, R. E. AU - Charnsangave, C. AU - Jonasch, E. PY - 2013 DA - 2013// TI - Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2013.06.003 DO - 10.1016/j.ejca.2013.06.003 ID - Matrana2013 ER - TY - JOUR AU - Rautiola, J. AU - Utriainen, T. AU - Peltola, K. AU - Joensuu, H. AU - Bono, P. PY - 2014 DA - 2014// TI - Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma JO - Acta Oncol VL - 53 UR - https://doi.org/10.3109/0284186X.2013.794957 DO - 10.3109/0284186X.2013.794957 ID - Rautiola2014 ER - TY - JOUR AU - Rodriguez Sanchez, A. AU - Garcia Dominguez, R. AU - Velasco, G. AU - Pinto, A. AU - Puente, J. AU - Rubio, G. AU - Vazquez-Estevez, S. AU - Juan, M. AU - Constenla, M. AU - Lopez Brea, M. PY - 2013 DA - 2013// TI - Pazopanib in metastatic renal carcinoma (mRC): Experience of 31 centers in Spain in first, second, third, or subsequent lines in daily clinical practice JO - ASCO Meeting Abstracts VL - 31 ID - Rodriguez Sanchez2013 ER - TY - JOUR AU - Xie, M. AU - He, C. S. AU - Huang, J. K. AU - Lin, Q. Z. PY - 2015 DA - 2015// TI - Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.01.005 DO - 10.1016/j.ejca.2015.01.005 ID - Xie2015 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - Tomczak, P. AU - Hutson, T. E. AU - Michaelson, M. D. AU - Negrier, S. AU - Oudard, S. AU - Gore, M. E. AU - Tarazi, J. AU - Hariharan, S. PY - 2013 DA - 2013// TI - Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70093-7 DO - 10.1016/S1470-2045(13)70093-7 ID - Motzer2013 ER - TY - JOUR AU - Qin, S. AU - Bi, F. AU - Jin, J. AU - Cheng, Y. AU - Guo, J. AU - Ren, X. AU - Huang, Y. AU - Tarazi, J. AU - Tang, J. AU - Chen, C. PY - 2015 DA - 2015// TI - Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study JO - Onco Targets Ther VL - 8 ID - Qin2015 ER - TY - JOUR AU - Sternberg, C. N. AU - Hawkins, R. E. AU - Wagstaff, J. AU - Salman, P. AU - Mardiak, J. AU - Barrios, C. H. AU - Zarba, J. J. AU - Gladkov, O. A. AU - Lee, E. AU - Szczylik, C. PY - 2013 DA - 2013// TI - A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.12.010 DO - 10.1016/j.ejca.2012.12.010 ID - Sternberg2013 ER - TY - JOUR AU - Escudier, B. AU - Porta, C. AU - Bono, P. AU - Powles, T. AU - Eisen, T. AU - Sternberg, C. N. AU - Gschwend, J. E. AU - Giorgi, U. AU - Parikh, O. AU - Hawkins, R. PY - 2014 DA - 2014// TI - Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.50.8267 DO - 10.1200/JCO.2013.50.8267 ID - Escudier2014 ER - TY - JOUR AU - Heng, D. Y. AU - Xie, W. AU - Regan, M. M. AU - Warren, M. A. AU - Golshayan, A. R. AU - Sahi, C. AU - Eigl, B. J. AU - Ruether, J. D. AU - Cheng, T. AU - North, S. PY - 2009 DA - 2009// TI - Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.21.4809 DO - 10.1200/JCO.2008.21.4809 ID - Heng2009 ER -